Contract manufacturing

We offer contract manufacturing capabilities leveraging the quality, reliability and flexibility of our manufacturing facilities. We operate 29 manufacturing plants across the US, Europe and the MENA region.

Leveraging our high-quality local manufacturing expertise.

For all business development enquiries contact:

US and Canada:



We offer a broad range of capabilities for oral, nasal and injectable products.


Dosage forms


Dosage forms

Prefilled syringe


IV bags




Large parenteral

Oral solutions

Small parenteral


Specialised products

Specialised products

Cytotoxic/high containment

High containment




Controlled substances

Controlled substances



World class contract manufacturing in Columbus, OH, US
You can call us on 614-308-3500


Advanced sterile injectable manufacturing operations in the US and Europe

Hikma’s Executive Vice Chairman and President of MENA Joins Rakuten Medical’s Board of Directors

Press Release, Corporate 07 March 2024

Hikma delivers strong 2023 performance and a positive outlook for 2024

Press Release, Financial Results 22 February 2024

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Press Release, Corporate 21 February 2024

Hikma launches Fentanyl Citrate Injection, USP, in a prefilled syringe in the US

Press Release, Product 20 February 2024

Hikma launches Alvimopan Capsules in the US

Press Release, Product 13 February 2024

Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...

Press Release, Business Development 12 February 2024

Notice of preliminary results

Press Release, Financial Results 05 February 2024

Hikma announces US launch of COMBOGESIC® IV

Press Release, Product 05 February 2024

Hikma appoints Julie Hill, as Senior Vice President, Corporate Quality Compliance/Health and Safety

Press Release, Leadership 01 February 2024

Hikma Announces Agreement in Principle for Nationwide US Opioid Settlement Framework

Press Release, Corporate 01 February 2024
Related content

Explore more